Loading
AP
Ascletis Pharma Inc. - B Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by WU Jinzi Jason, was filed 13 Jan 2025.
Ascletis Pharma Inc. - B: what insiders have been doing
Every trade that managers of Ascletis Pharma Inc. - B disclose to HKEX is tracked on this page. The company sits in the Health Care sector. Ascletis Pharma Inc. - B has had no insider filing for more than a year; the last one goes back to 27 August 2025.
Our records for Ascletis Pharma Inc. - B go back to 2018, with 15 purchases and 1 sale on the open market in total.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Insider Decl.
48
Thresholds
n/a
Buy Volume
€6M
15 ops. · all time
Sell Volume
€43M
1 ops. · all time
Who traded when
BuySaleWU Jinzi Jason3 buys1 sale
Since the insiders bought
- +305.4%Entry 3.34 · Close at T+365 13.54
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Last declaration on 27 August 2025
Declarations48 total
23,580,000 shares@ HK$16.4587.1% of flowShareXHKGHKEX:DA20250827E00010
23,580,000 shares@ HK$16.4587.1% of flowShareXHKGHKEX:DA20250827E00011
300,000 shares@ HK$3.05480.2% of flowShareXHKGHKEX:DA20250113E00293
Canonical exit: 9 Apr 2025 (T+90)
300,000 shares@ HK$3.05480.2% of flowShareXHKGHKEX:DA20250113E00297
Canonical exit: 9 Apr 2025 (T+90)
3,973,000 shares@ HK$1.66431.6% of flowShareXHKGHKEX:DA20241217E00375
Canonical exit: 18 Feb 2025 (T+90)
6,043,000 shares@ HK$1.44262.1% of flowShareXHKGHKEX:DA20241217E00372
Canonical exit: 2 Feb 2025 (T+90)
2,400,000 shares@ HK$1.26520.7% of flowShareXHKGHKEX:DA20241217E00370
Canonical exit: 14 Jan 2025 (T+90)
7,470,000 shares@ HK$1.38962.5% of flowShareXHKGHKEX:DA20241217E00369
Canonical exit: 6 Jan 2025 (T+90)
3,189,000 shares@ HK$0.97460.7% of flowShareXHKGHKEX:DA20241217E00368
Canonical exit: 23 Dec 2024 (T+90)
3,977,000 shares@ HK$0.93610.9% of flowShareXHKGHKEX:DA20241217E00367
Canonical exit: 15 Dec 2024 (T+90)
5,324,000 shares@ HK$0.98991.2% of flowShareXHKGHKEX:DA20241217E00366
Canonical exit: 8 Dec 2024 (T+90)
4,363,000 shares@ HK$1.15941.2% of flowShareXHKGHKEX:DA20241217E00364
Canonical exit: 23 Oct 2024 (T+90)
3,973,000 shares@ HK$1.66431.6% of flowShareXHKGHKEX:DA20241217E00383
Canonical exit: 18 Feb 2025 (T+90)
6,043,000 shares@ HK$1.44262.1% of flowShareXHKGHKEX:DA20241217E00382
Canonical exit: 2 Feb 2025 (T+90)
2,400,000 shares@ HK$1.26520.7% of flowShareXHKGHKEX:DA20241217E00381
Canonical exit: 14 Jan 2025 (T+90)
7,470,000 shares@ HK$1.38962.5% of flowShareXHKGHKEX:DA20241217E00380
Canonical exit: 6 Jan 2025 (T+90)
3,189,000 shares@ HK$0.97460.7% of flowShareXHKGHKEX:DA20241217E00379
Canonical exit: 23 Dec 2024 (T+90)
3,977,000 shares@ HK$0.93610.9% of flowShareXHKGHKEX:DA20241217E00378
Canonical exit: 15 Dec 2024 (T+90)
5,324,000 shares@ HK$0.98991.2% of flowShareXHKGHKEX:DA20241217E00377
Canonical exit: 8 Dec 2024 (T+90)
4,363,000 shares@ HK$1.15941.2% of flowShareXHKGHKEX:DA20241217E00376
Canonical exit: 23 Oct 2024 (T+90)
1,155,500 sharesShareXHKGHKEX:DA20240115E00011
1,155,500 sharesShareXHKGHKEX:DA20240115E00015
1,000,000 sharesShareXHKGHKEX:DA20240105E00128
Canonical exit: 2 Apr 2024 (T+90)
1,000,000 sharesShareXHKGHKEX:DA20240105E00132
Canonical exit: 2 Apr 2024 (T+90)
0ShareXHKGHKEX:DA20220905E00636
25 of 48 declarations
About Ascletis Pharma Inc. - B
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing treatments for viral diseases and cancer. It is listed on the Hong Kong Stock Exchange under the symbol XHKG.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
